TY - JOUR
T1 - Efficacy and tolerability of the dual 5α-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men
AU - Roehrborn, Claus
AU - Ray, P.
PY - 2006/12
Y1 - 2006/12
N2 - The efficacy and tolerability of dutasteride (0.5mg daily for 2 years) in African-Americans (n=161), compared with Caucasians (n=3961), was assessed in a post hoc analysis of data from three Phase III clinical trials. Dutasteride significantly reduced serum dihydrotestosterone levels by >90% and significantly improved subjective (symptom score) and objective (prostate volume, peak urinary flow rate, risk of benign prostatic hyperplasia-related surgery and acute urinary retention) outcomes in both African-Americans and Caucasians. For all efficacy measures, there was no statistically significant treatment-by-race interaction and dutasteride was well tolerated in both racial groups. Therefore, dutasteride demonstrated similar efficacy and safety profiles in African-Americans and Caucasians.
AB - The efficacy and tolerability of dutasteride (0.5mg daily for 2 years) in African-Americans (n=161), compared with Caucasians (n=3961), was assessed in a post hoc analysis of data from three Phase III clinical trials. Dutasteride significantly reduced serum dihydrotestosterone levels by >90% and significantly improved subjective (symptom score) and objective (prostate volume, peak urinary flow rate, risk of benign prostatic hyperplasia-related surgery and acute urinary retention) outcomes in both African-Americans and Caucasians. For all efficacy measures, there was no statistically significant treatment-by-race interaction and dutasteride was well tolerated in both racial groups. Therefore, dutasteride demonstrated similar efficacy and safety profiles in African-Americans and Caucasians.
UR - http://www.scopus.com/inward/record.url?scp=33751585406&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33751585406&partnerID=8YFLogxK
U2 - 10.1038/sj.pcan.4500911
DO - 10.1038/sj.pcan.4500911
M3 - Article
C2 - 16983393
AN - SCOPUS:33751585406
SN - 1365-7852
VL - 9
SP - 432
EP - 438
JO - Prostate Cancer and Prostatic Diseases
JF - Prostate Cancer and Prostatic Diseases
IS - 4
ER -